US FDA grants customary approval of EisaiBiogen Alzheimer’s drug Leqembi, widening entry to the remedy
Los Angeles: Eisai and Biogen’s Leqembi gained a coveted customary approval nod from the US Meals and Drug Administration on Thursday, the primary Alzheimer’s therapy to realize that purpose, clearing the best way for wider insurance coverage protection of the…